Type 2 diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention (Case): Glibenclamide (10 mg/day) + Metformin (1000 mg/day) + L-Lys (3 g/day) for 3 months. Intervention 2: Control: Glibenclamide (10 mg/day) + Metformin (1000 mg/day) f
Treatment - Drugs
Intervention (Case): Glibenclamide (10 mg/day) + Metformin (1000 mg/day) + L-Lys (3 g/day) for 3 months
Control: Glibenclamide (10 mg/day) + Metformin (1000 mg/day) for 3 months
Sponsors
Iran National Science Foundation (INSF)
Eligibility
Sex/Gender
All
Age
41 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Glycated hemoglobin (HbA1c) = 7%; normal serum insulin level; no history of ketoacidosis, cancer, hyper- or hypothyroidism, diabetic ulcer, chronic renal failure, liver cirrhosis, feverish diseases and consumption of corticosteroids; with serum creatinine = 2 mg/dl; no symptom of hypoinsulinemia such as ketonuria, weight loss; serum glucose level more than 400 mg/dl. Exclusion Criteria: no response to oral agents; need for insulin therapy; appearance of diabetic ulcer or feverish diseases during treatment.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting Blood Sugar. Timepoint: 3 Months. Method of measurement: Enzymatic Colorimetric.;Hemoglobin A1c. Timepoint: 3 Months. Method of measurement: HPLC. | — |
Secondary
| Measure | Time frame |
|---|---|
| Insulin Resistance. Timepoint: 3 months. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Mirmiranpour
Tehran University of Medical Sciences
Outcome results
None listed